



**DEPARTMENT OF BIOSCIENCE
TOKYO UNIVERSITY OF AGRICULTURE**

TAKANOBU NAKAZAWA, Ph.D. PROFESSOR
1-1-1 SAKURAGAOKA, SETAGAYA-KU, TOKYO 156-8502, JAPAN
PHONE/FAX: +81 (3) 5477-2318; E-mail: tn207427@nodai.ac.jp

CURRICULUM VITAE

NAME Takanobu NAKAZAWA

POSITION Professor, Graduate School of Life Sciences,
Tokyo University of Agriculture,
1-1-1 Sakuragaoka, Setagaya-ku, Tokyo 156-8502, Japan

E-mail tn207427@nodai.ac.jp
Phone +81-3-5477-2318
FAX +81-3-5477-2318

DATE AND PLACE OF BIRTH August 24, 1972, Kanagawa, Japan

EDUCATION AND EXPERIENCE

1992-1996 Bachelor of Agricultural Chem., University of Tokyo
Thesis title
“Pseudohyphal growth of dimorphic yeast, *Candida maltosa*”
Supervisor: Prof. Masamichi Takagi

1996-1998 Master of Applied Biotech., University of Tokyo
Thesis title
“Morphological transition of dimorphic yeast, *Candida maltosa*”
Supervisor: Prof. Masamichi Takagi

1998-2002 Ph.D. in Med. Sci., University of Tokyo
Thesis title “The role of tyrosine phosphorylation of the NMDA
receptor”
Supervisor: Prof. Tadashi Yamamoto

2002-2005 Research Fellow of the Japan Society for the Promotion of Science,
the Ministry of Education, Science, Sports, Culture, and Technology
of Japan
“The role of tyrosine phosphorylation in higher brain functions”

2005-2011 Research Associate,
Institute of Medical Science, University of Tokyo
“Molecular and cellular mechanism of dendritic spine development”

2011-2013 Lecturer,
Graduate School of Medicine, University of Tokyo
“Molecular and cellular pathogenesis of psychiatric disorders”

2013-2016 Associate Professor,

Graduate School of Pharmaceutical Sciences, Osaka University
“Modeling psychiatric disorders with iPSC technology and disease-model mice”

2016-2020 Associate Professor,
Graduate School of Dentistry, Osaka University
“Modeling psychiatric disorders with iPSC technology and disease-model mice”

2020-Present Professor
Graduate School of Life Sciences, Tokyo University of Agriculture
“Modeling psychiatric disorders with iPSC technology and disease-model mice”

FELLOWSHIP April, 1999-March, 2002 Japan Society for the Promotion of
Science fellowships for Japanese Junior Scientists (for
graduate student)

April, 2002-January, 2005 Japan Society for the Promotion of
Science fellowships for Japanese Junior Scientists (for
postdoctoral fellow)

MEMBERSHIP The Molecular Biology Society of Japan
The Japan Neuroscience Society
The Japanese Society for Neurochemistry
The Physiological Society of Japan
The Japanese Society of Neuropsychopharmacology
The Pharmaceutical Society of Japan
Japan Society of Nutrition and Food Science
Japanese Society of Biological Psychiatry
Japan Society for Bioscience, Biotechnology, and Agrochemistry
Society for Neuroscience, USA

REFERENCES

1. Nagai Y, Kisaka Y, Nomura K, Nishitani N, Andoh C, Koda M, Kawai H, Seiriki K, Nagayasu K, Kasai A, Shirakawa H, **Nakazawa T**, Hashimoto H, Kaneko S. Dorsal raphe serotonergic neurons preferentially reactivate dorsal dentate gyrus cell ensembles associated with positive experience. *Cell Rep* 42:112149 (2023).
2. Asano S, Ono A, Sakamoto K, Hayata-Takano A, **Nakazawa T**, Tanimoto K, Hashimoto H, Ago Y. Vasoactive intestinal peptide receptor 2 signaling promotes breast cancer cell proliferation by enhancing the ERK pathway. *Peptides* 2:170940 (2023).
3. Asano S, Yamasaka M, Ozasa K, Sakamoto K, Hayata-Takano A, **Nakazawa T**, Hashimoto H, Waschek JA, Ago Y. Vasoactive intestinal peptide-VIPR2 signaling regulates tumor cell migration. *Front. Oncol.* 12:852358 (2022).
4. Takemoto T, Baba M, Yokoyama K, Kitagawa K, Nagayasu K, Ago Y, Seiriki K, Hayata-Takano A, Kasai A, Mori D, Ozaki N, Takuma K, Hashimoto R, Hashimoto H, **Nakazawa T**. Oxytocin ameliorates impaired social behavior in a mouse model of 3q29 deletion syndrome. *Mol. Brain* 15:26 (2022).
5. Kawano S, Baba M, Fukushima H, Miura D, Hashimoto H, **Nakazawa T**. Autism-associated ANK2 regulates embryonic neurodevelopment. *Biochem. Biophys. Res. Commun.* 605:45-50 (2022).

6. Niu M, Kasai A, Tanuma M, Seiriki K, Igarashi H, Kuwaki T, Nagayasu K, Miyaji K, Ueno H, Tanabe W, Seo K, Yokoyama R, Ohkubo J, Ago Y, Hayashida M, Inoue KI, Takada M, Yamaguchi S, **Nakazawa T**, Kaneko S, Okuno H, Yamanaka A, Hashimoto H. Claustrum mediates bidirectional and reversible control of stress-induced anxiety responses. *Sci. Adv.* 8:eabi6375 (2022).
7. **Nakazawa T**. Modeling schizophrenia with iPS cell technology and disease mouse models. *Neurosci. Res.* 175:46-52 (2022). Review
8. Onitsuka T, Hirano Y, **Nakazawa T**, Ichihashi K, Miura K, Inada K, Mitoma R, Yasui-Furukori N, Hashimoto R. Toward recovery in schizophrenia: Current concepts, findings, and future research directions. *Psychiatry Clin. Neurosci.* 76:282-291 (2022). review
9. Onitsuka T, Hirano Y, Nemoto K, Hashimoto N, Kushima I, Koshiyama D, Koeda M, Takahashi T, Noda Y, Matsumoto J, Miura K, **Nakazawa T**, Hikida T, Kasai K, Ozaki N, Hashimoto R. Trends in big data analyses by multicenter collaborative translational research in psychiatry. *Psychiatry Clin. Neurosci.* 76:1-14 (2022).
10. Hayata-Takano A, Shintani Y, Moriguchi K, Encho N, Kitagawa K, **Nakazawa T**, Hashimoto H. PACAP-PAC1 signaling regulates serotonin 2A receptor internalization. *Front. Endocrinol.* 12:732456 (2021).
11. Yamamoto K, Kuriu T, Matsumura K, Nagayasu K, Tsurusaki Y, Miyake N, Yamamori H, Yasuda Y, Fujimoto M, Fujiwara M, Baba M, Kitagawa K, Takemoto T, Gotoda-Nishimura N, Takada T, Seiriki K, Hayata-Takano A, Kasai A, Ago Y, Kida S, Takuma K, Ono F, Matsumoto N, Hashimoto R, Hashimoto H, **Nakazawa T**. Multiple alterations in glutamatergic transmission and dopamine D2 receptor splicing in induced pluripotent stem cell-derived neurons from patients with familial schizophrenia. *Transl. Psychiatry* 11:548 (2021).
12. Togo K, Fukusumi H, Shofuda T, Ohnishi H, Yamazaki H, Hayashi MK, Kawasaki N, Takei N, **Nakazawa T**, Saito Y, Baba K, Hashimoto H, Sekino Y, Shirao T, Mochizuki H, Kanemura Y. Postsynaptic structure formation of human iPSC-derived neurons takes longer than presynaptic formation during neural differentiation in vitro. *Mol. Brain* 14:149 (2021).
13. Kikuchi M, **Nakazawa T**, Kinoshita M, Yamamori H, Yasuda Y, Fujimoto M, Hashimoto R, Numata S. Methylation analysis in monozygotic twins with treatment-resistant schizophrenia and discordant responses to clozapine. *Front. Psychiatry* 12:734606 (2021).
14. Lai ESK, Nakayama H, Miyazaki T, **Nakazawa T**, Tabuchi K, Hashimoto K, Watababe M, Kano M. An autism-associated Neuroligin-3 mutation affects developmental synapse elimination in the cerebellum. *Front. Neural Circuits* 15:676891 (2021).
15. Kitagawa K, Matsumura K, Baba M, Kondo M, Takemoto T, Nagayasu K, Ago Y, Seiriki K, Hayata-Takano A, Kasai A, Takuma K, Hashimoto R, Hashimoto H, **Nakazawa T**. Intranasal oxytocin administration ameliorates social behavioral deficits in a POGZ^{WT/Q1038R} mouse model of autism spectrum disorder. *Mol. Brain* 14:56 (2021).
16. Kawaguchi C, Shintani N, Hayata-Takano A, Hatanaka M, Kuromi A, Nakamura R, Yamamo Y, Shintani Y, Nagai K, Tsuchiya S, Sugimoto Y, Ichikawa A, Okuno Y, Urade Y, Hirai H, Nagata Ky, Nakamura M, Narumiya S, **Nakazawa T**, Kasai A, Ago Y, Takuma K, Baba A, Hashimoto H. Lipocaine-type prostaglandin D synthase regulates light-induced phase advance of the central circadian rhythm in mice. *Commun. Biol.* 3:557 (2020).
17. Takeuchi S, Kawanai T, Yamauchi R, Chen L, Miyaoka T, Yamada M, Asano S, Hayata-Takano A, **Nakazawa T**, Yano K, Horiguchi N, Nakagawa S, Takuma K, Waschek JA, Hashimoto H, Ago Y. Activation of the VPAC2 receptor impairs axon outgrowth and decreases dendritic arborization in mouse cortical neurons by a PKA-dependent mechanism. *Front. Mol. Neurosci.* 14:521 (2020).
18. Matsumura K, Seiriki K, Okada S, Nagase M, Ayabe S, Yamada I, Furuse T, Shibuya H, Yasuda Y, Yamamori H, Fujimoto M, Nagayasu K, Yamamoto K, Kitagawa K, Miura H, Gotoda-Nishimura N, Igarashi H, Hayashida M, Baba M, Kondo M, Hasebe S, Ueshima K, Kasai A, Ago Y, Hayata-Takano A, Shintani N, Iguchi T, Sato M, Yamaguchi S, Tamura M, Wakana S, Yoshiki A, Watabe AM, Okano H, Takuma K, Hashimoto R, Hashimoto H, **Nakazawa T**. Pathogenic POGZ mutation causes impaired cortical development and reversible autism-like phenotypes.

Nat. Commun. 11:859 (2020).

19. Yokoyama R, Higuchi M, Tanabe W, Tsukada S, Naito M, Yamaguchi T, Chen L, Kasai A, Seiriki K, **Nakazawa T**, Nakagawa S, Hashimoto K, Hashimoto H, Ago Y. (S)-norketamine and (2S,6S)-hydroxynorketamine exert potent antidepressant-like effects in a chronic corticosterone-induced mouse model of depression. *Pharmacol. Biochem. Behav.* 191:172876 (2020).
20. Matsumura K, Baba M, Nagayasu K, Yamamoto K, Kondo M, Kitagawa K, Takemoto T, Seiriki K, Kasai A, Ago Y, Hayata-Takano A, Shintani N, Kuriu T, Iguchi T, Sato M, Takuma K, Hashimoto R, Hashimoto H, **Nakazawa T**. Autism-associated protein kinase D2 regulates embryonic cortical neuron development. *Biochem. Biophys. Res. Commun.* 519:626-632 (2019).
21. Ago Y, Tanabe W, Higuchi M, Tsukada S, Tanaka T, Yamaguchi T, Igarashi H, Yokoyama R, Seiriki K, Kasai A, **Nakazawa T**, Nakagawa S, Hashimoto K, Hashimoto H. (R)-ketamine induces a greater increase in prefrontal 5-HT release than (S)-ketamine and ketamine metabolites via an AMPA receptor-independent mechanism. *Int. J. Neuropsychopharmacol.* 22:665-674 (2019).
22. **Nakazawa T**, Hashimoto R, Takuma K, Hashimoto H. Modeling of psychiatric disorders using induced pluripotent stem cell-related technologies. *J. Pharmacol. Sci.* 140:321-324 (2019). review
23. Baba M, Yokoyama K, Seiriki K, Naka Y, Matsumura K, Kondo M, Yamamoto K, Hayashida M, Kasai A, Ago Y, Nagayasu K, Hayata-Takano A, Takahashi A, Yamaguchi S, Mori D, Ozaki N, Yamamoto T, Takuma K, Hashimoto R, Hashimoto H, **Nakazawa T**. Psychiatric-disorder-related behavioral phenotypes and cortical hyperactivity in a mouse model of 3q29 deletion syndrome. *Neuropsychopharmacol.* 44:2125-2135 (2019).
24. Seiriki K, Kasai A, **Nakazawa T**, Niu M, Naka Y, Tanuma M, Igarashi H, Yamaura K, Hayata-Takano A, Ago Y, Hashimoto H. Whole-brain block-face serial microscopy tomography at subcellular resolution using FAST. *Nat. Protocols* 14:1509-1529 (2019).
25. Hayata-Takano A, Kamo T, Kijima H, Seiriki K, Ogata K, Ago Y, **Nakazawa T**, Shintani Y, Higashino K, Nagayasu K, Shintani N, Kasai A, Waschek JA, Hashimoto H. Pituitary adenylate cyclase-activating polypeptide modulates dendritic spine maturation and morphogenesis via microRNA-132 upregulation. *J. Neurosci.* 39:4208-4220 (2019).
26. Kawase H, Ago Y, Naito M, Higuchi M, Hara Y, Hasebe S, Tsukada S, Kasai A, **Nakazawa T**, Mishina T, Kouji H, Takuma K, Hashimoto H. ms-11, a mimetic of the msin3-binding helix in NRSF, ameliorates social interaction deficits in a prenatal valproic acid-induced autism mouse model. *Pharmacol. Biochem. Behav.* 176:1-5 (2019).
27. Shintani Y, Hayata-Takano A, Moriguchi K, **Nakazawa T**, Ago Y, Kasai A, Seiriki K, Shintani N, Hashimoto H. β -arrestin1 and 2 differentially regulate PACAP-induced PAC1 receptor signaling and trafficking. *PLoS ONE* 13:e0196946 (2018).
28. Inoue N, Ogura S, Kasai A, **Nakazawa T**, Ikeda K, Higashi S, Isotani A, Baba K, Mochizuki H, Fujimura H, Ago Y, Hayata-Takano A, Seiriki K, Shintani Y, Shintani N, Hashimoto H. Knockdown of the mitochondria-localized protein p13 protects against experimental parkinsonism. *EMBO Rep.* 19:e44860 (2018).
29. Inoue N, Hirouchi T, Kasai A, Higashi S, Hiraki N, Tanaka S, **Nakazawa T**, Nunomura K, Lin B, Omori A, Hayata-Takano A, Kim Y, Doi T, Baba A, Hashimoto H, Shintani N. Unbiased compound screening with a reporter gene assay highlights the role of p13 in the cardiac cellular stress response. *Biochem. Biophys. Res. Commun.* 495:1992-1997 (2018).
30. Hara Y, Ago Y, Higuchi M, Hasebe S, **Nakazawa T**, Hashimoto H, Matsuda T, Takuma K. Oxytocin attenuates deficits in social interaction but not recognition memory in a prenatal valproic acid-induced mouse model of autism. *Horm. Behav.* 96:130-136 (2017).
31. Hara Y, Ago Y, Taruta A, Hasebe S, Kawase H, Tanabe W, Tsukada S, **Nakazawa T**, Hashimoto H, Matsuda T, Takuma K. Risperidon and aripiprazole alleviate prenatal valproic acid-induced abnormalities in behaviors and dendritic spine density in mice. *Psychopharmacol.* 234:3217-3228 (2017).

32. Yamaguchi H, Hara Y, Ago Y, Takano E, Hasebe S, **Nakazawa T**, Hashimoto H, Matsuda T, Takuma K. Environmental enrichment attenuates behavioral abnormalities in valproic acid-exposed autism model mice.
Behav. Brain Res. 333:67-73 (2017).
33. Hara Y, Ago Y, Takano E, Hasebe S, **Nakazawa T**, Hashimoto H, Matsuda T, Takuma K. Prenatal exposure to valproic acid increases miR-132 levels in the mouse embryonic brain.
Mol. Autism 8:33 (2017).
34. Choo M, Miyazaki T, Yamasaki M, Kawamura M, **Nakazawa T**, Zhang J, Tanimura A, Uesaka N, Watanabe M, Sakimura K, Kano M. Retrograde BDNF to TrkB signaling promotes synapse elimination in the developing cerebellum.
Nat. Commun. 8:195 (2017).
35. Seiriki K, Kasai A, Hashimoto T, Schulze W, Niu M, Yamaguchi S, **Nakazawa T**, Inoue K, Uezono S, Takada M, Naka Y, Igarashi H, Tanuma M, Waschek JA, Ago Y, Tanaka KF, Hayata-Takano A, Nagayasu K, Shintani N, Hashimoto R, Kunii Y, Hino M, Matsumoto J, Yabe H, Nagai T, Fujita K, Matsuda T, Takuma K, Baba A, Hashimoto H. High-speed and scalable whole-brain imaging in rodents and primates.
Neuron 94:1085-1100 (2017).
36. Kinoshita M, Numata S, Tajima A, Yamamori H, Yasuda Y, Fujimoto M, Watanabe S, Umehara H, Shimodera S, **Nakazawa T**, Kikuchi M, Nakaya A, Hashimoto H, Imoto I, Hashimoto R, Ohmori T. Effect of clozapine on DNA methylation in peripheral leukocytes from patients with treatment-resistant schizophrenia.
Int. J. Mol. Sci. 18(3).pii:E632 (2017).
37. **Nakazawa T**, Kikuchi M, Ishikawa M, Yamamori H, Nagayasu K, Matsumoto T, Fujimoto M, Yasuda Y, Fujiwara M, Okada S, Matsumura K, Kasai A, Hayata-Takano A, Shintani N, Numata S, Takuma K, Akamatsu W, Okano H, Nakaya A, Hashimoto H, Hashimoto R. Differential gene expression profiles in neurons generated from lymphoblastoid B-cell line-derived iPS cells from monozygotic twin cases with treatment-resistant schizophrenia and discordant responses to clozapine.
Schizo. Res. 181:75-82 (2017).
38. Kasai A, Kakihara S, Miura H, Okada R, Hayata-Takano A, Hazama K, Niu M, Shintani N, **Nakazawa T**, Hashimoto H. Double in situ hybridization for microRNAs and mRNAs in brain tissues.
Front. Mol. Neurosci. 9:126 (2016).
39. Seiriki K, Kasai A, Kuwaki T, **Nakazawa T**, Yamaguchi S, Hashimoto H. Critical involvement of the orbitofrontal cortex in hyperlocomotion induced by NMDA receptor blockade in mice.
Biochem. Biophys. Res. Commun. 480:558-563 (2016).
40. Katano T, Fukuda M, Furue H, Yamazaki M, Abe M, Watanabe M, Nishida K, Yao I, Yamada A, Hata Y, Okumura N, **Nakazawa T**, Yamamoto T, Sakimura K, Takao T, Ito S. Involvement of brain-enriched guanylate kinase-associated protein (BEGAIN) in chronic pain after peripheral nerve injury.
eNeuro 3:e0110-16 (2016).
41. Onaka Y*, Shintani N*, **Nakazawa T***, Kanoh T*, Ago Y, Matsuda T, Hashimoto R, Ohi K, Hirai H, Nagata K, Nakamura M, Kasai A, Hayata-Takano A, Nagayasu K, Takuma K, Ogawa A, Baba A, Hashimoto H. Prostaglandin D₂ signaling mediated by the CRTH2 receptor is involved in MK-801-induced cognitive dysfunction. (* equal 1st author)
Behav. Brain Res. 314:77-86 (2016).
42. Inoue A, Uchida H, **Nakazawa T**, Yamamoto T, Ito S. Phosphorylation of NMDA receptor GluN2B subunit at Tyr1472 is important for trigeminal processing of itch.
Eur. J. Neurosci. 44:2474-2482 (2016).
43. Matsumura K, **Nakazawa T**^{CA}, Nagayasu K, Gotoda-Nishimura N, Kasai A, Hayata-Takano A, Shintani N, Yamamori H, Yasuda Y, Hashimoto R, Hashimoto H. *De novo* POGZ mutations in sporadic autism disrupt the DNA-binding activity of POGZ. (CA corresponding author)
J. Mol. Psychiatry 4:1 (2016).
44. **Nakazawa T**^{CA}, Hashimoto R^{CA}, Sakoori K, Sugaya Y, Tanimura A, Hashimoto Y, Ohi K, Yamamori H, Yasuda Y, Umeda-Yano S, Kiyama Y, Konno K, Inoue T, Yokoyama K, Inoue T, Numata S, Ohnuma T, Iwata N, Ozaki N, Hashimoto H, Watanabe M, Manabe T, Yamamoto T, Takeda M, Kano M^{CA}. Emerging roles of ARHGAP33 in intracellular trafficking of TrkB and pathophysiology of neuropsychiatric disorders. (CA corresponding author)
Nat. Commun. 7:10594 (2016).

45. Hashimoto R^{CA}, **Nakazawa T**^{CA}, Tsurusaki Y, Yasuda Y, Nagayasu K, Matsumura K, Kawasaki H, Yamamori H, Fujimoto M, Ohi K, Umeda-Yano S, Fukunaga M, Fujino H, Kasai A, Hayata-Takano A, Shintani N, Takeda M, Matsumoto N, Hashimoto H. Whole-exome sequencing and neurite outgrowth analysis in autism spectrum disorder. (^{CA} equal corresponding author)
J. Hum. Genet. 61:199-206 (2016).
46. Ikeda K, Tomimoto S, Tsuchiya S, Hamagami K, Shintani N, Sugimoto Y, Ichikawa A, Kasai A, **Nakazawa T**, Nagayasu K, Hayata-Takano A, Baba A, Hashimoto H. Comparative gene expression profiles in pancreatic islets associated with Agouti yellow mutation and PACAP overexpression in mice.
Biochem. Biophys. Reports 2:179-183 (2015).
47. Higashi S, Katagi K, Shintani N, Ikeda K, Sugimoto Y, Inoue N, Tanaka S, Koumoto M, Kasai A, **Nakazawa T**, Hayata-Takano A, Hamagami K, Tomimoto S, Yoshida T, Ohkubo T, Nagayasu K, Ago Y, Onaka Y, Hashimoto R, Ichikawa A, Baba A, Hashimoto H. p13 overexpression in pancreatic β -cells exerts multiple protective effects against type 2 diabetes in high-fat-fed mice.
Biochem. Biophys. Res. Commun. 461:612-617 (2015).
48. Shibasaki Y*, Hayata-Takano A*, Hazama K*, **Nakazawa T***, Shintani N, Kasai A, Nagayasu K, Hashimoto R, Tanida M, Katayama T, Matsuzaki S, Yamada K, Taniike M, Onaka Y, Ago Y, Waschek JA, Köves K, Reglodi D, Tamas A, Matsuda T, Baba A, Hashimoto H. Atomoxetine reverses locomotor hyperactivity, impaired novel object recognition, and prepulse inhibition impairment in mice lacking pituitary adenylate cyclase-activating polypeptide (PACAP). (* equal 1st author)
Neuroscience 297:95-104 (2015).
49. Schulze W, Hayata-Takano A, Kamo T, **Nakazawa T**^{CA}, Nagayasu K, Kasai A, Seiriki K, Shintani N, Ago Y, Farfan C, Hashimoto R, Baba A, Hashimoto H^{CA}. Simultaneous neuron- and astrocyte-specific fluorescent marking. (^{CA} equal corresponding author)
Biochem. Biophys. Res. Commun. 459:81-86 (2015).
50. Onaka Y*, Shintani N*, **Nakazawa T***, Haba R*, Ago Y, Wang H, Kanoh T, Hayata-Takano A, Hirai H, Nagata K, Nakamura M, Hashimoto R, Matsuda T, Waschek JA, Kasai A, Nagayasu K, Baba A, Hashimoto H. CRTH2, a prostaglandin D2 receptor, mediates depression-related behavior in mice. (* equal 1st author)
Behav. Brain Res. 284:131-137 (2015).
51. Ogata K, Shintani N, Hayata-Takano A, Kamo T, Higashi S, Seiriki K, Momosaki H, Vaudry D, Vaudry H, Galas L, Kasai A, Nagayasu K, **Nakazawa T**, Hashimoto R, Ago Y, Matsuda T, Baba A, Hashimoto H. PACAP enhances axon and neurite outgrowth in cultured hippocampal neurons to a comparable extent as BDNF.
PLoS ONE 10:e0120526 (2015).
52. Yamasaki A, Kasai A, Toi A, Kurita M, Kimoto S, Hayata-Takano A, **Nakazawa T**, Nagayasu K, Shintani N, Hashimoto R, Ito A, Meltzer HY, Ago Y, Waschek JA, Onaka Y, Matsuda M, Baba A, Hashimoto H. Identification of the role of BMP and TGF- β signaling in the trajectory of serotonergic differentiation in a rapid assay in mouse embryonic stem cells *in vitro*.
J. Neurochem. 132:418-428 (2015).
53. Shintani N, Onaka Y, Hashimoto R, Takamura H, Nagata T, Umeda-Yano S, Mouri A, Mamiya T, Haba R, Matsuzaki S, Katayama T, Yamamori H, **Nakazawa T**, Nagayasu K, Ago Y, Yagasaki Y, Nabeshima T, Takeda M, Hashimoto H. Behavioral characterization of mice overexpressing human dysbindin-1.
Mol. Brain 7:74 (2014).
54. Knox R, Brennan AM, Lu F, Yang D, **Nakazawa T**, Yamamoto T, Swanson RA, Jiang X. NR2B phosphorylation at Tyrosine 1472 contributes to brain injury in a rodent model of neonatal hypoxia-ischemia.
Stroke 45:3040-3047 (2014).
55. David O, Barrera I, Chinnakkaruppan A, Kapjzan H, **Nakazawa T**, Yamamoto T, Rosenblum K. Dopamine-induced tyrosine phosphorylation of NR2B (Tyr1472) is essential for ERK1/2 activation and processing of novel taste information.
Front. Mol. Neurosci. 7:66 (2014).
56. Dhar M, Zhu M, Impey S, Lambert TJ, Karatsoreos IN, **Nakazawa T**, Appleyard SM, Wayman GA. Leptin induces hippocampal synaptogenesis via CREB-regulated microRNA-132 suppression of p250GAP.
Mol. Endocrinol. 28:1073-1087 (2014).
57. Uesaka N, Uchigashima M, Mikuni T, **Nakazawa T**, Nakao H, Hirai H, Aiba A, Watanabe M, Kano M. Retrograde semaphorin signaling regulates synapse elimination in the developing mouse brain.
Science 344:1020-1023 (2014).

58. Inoue T, Hoshina N, **Nakazawa T**, Kiyama Y, Kobayashi S, Abe T, Yamamoto T, Manabe T, Yamamoto T. LMTK3 deficiency causes pronounced locomotor hyperactivity and impairs endocytic trafficking. *J. Neurosci.* 34:5927-5937 (2014).
59. Hazama K, Hayata-Takano A, Uetsuki K, Kasai A, Encho N, Shintani N, Nagayasu K, Hashimoto R, Reglodi D, Miyakawa T, **Nakazawa T**, Baba A, Hashimoto H. Increased behavioral and neuronal responses to a hallucinogenic drug in PACAP heterozygous mutant mice. *PLoS ONE* 9:e89153 (2014).
60. Haba R, Shintani N, Onaka Y, Kanoh T, Wang H, Takenaga R, Hayata A, Hirai H, Nagata KY, Nakamura M, Kasai A, Hashimoto R, Nagayasu K, **Nakazawa T**, Hashimoto H, Baba A. Central CRTH2, a second prostaglandin D₂ receptor, mediates emotional impairment in the lipopolysaccharide and tumor-induced sickness behavior model. *J. Neurosci.* 34:2514-2523 (2014).
61. Hoshina N, Tanimura A, Yamasaki M, Inoue T, Fukabori R, Kuroda T, Yokoyama K, Tezuka T, Sagara H, Hirano S, Kiyonari H, Takada M, Kobayashi K, Watanabe M, Kano M, **Nakazawa T**, Yamamoto T. Protocadherin 17 regulates presynaptic assembly in topographic corticobasal ganglia circuits. *Neuron* 78:839-854 (2013).
62. Kannan M, Lee SJ, Schwedhelm-Domeyer N, **Nakazawa T**, Stegmüller J. p250GAP is a novel player in the Cdh1-APC/Smurf1 pathway of axon growth regulation. *PLoS ONE* 7:e50735 (2012).
63. Unezaki S, Sasaki A, Mabuchi T, Matsumura S, Katano T, **Nakazawa T**, Nishio N, Andoh T, Yamamoto T, Nakatsuka T, Kuraishi Y, Ito S. Involvement of Tyr1472 phosphorylation of NMDA receptor NR2B subunit in postherpetic neuralgia in model mice. *Mol. Pain* 8:59 (2012).
64. Delawary M, Tezuka T, Kiyama Y, Yokoyama K, Wada E, Wada K, Manabe T, Yamamoto T, **Nakazawa T**.^{CA} NMDAR2B tyrosine phosphorylation is involved in thermal nociception. (^{CA} corresponding author) *Neurosci. Lett.* 516:270-273 (2012).
65. Ohi K, Hashimoto R, **Nakazawa T**, Okada T, Yasuda Y, Yamamori H, Fukumoto M, Umeda-Yano S, Iwase M, Kazui H, Yamamoto T, Kano M, Takeda M. The p250GAP gene is associated with risk for schizophrenia and schizotypal personality trait. *PLoS ONE* 7:e35696 (2012).
66. Yang K, Trepanier C, Sidhu B, Xie YF, Li H, Lei G, Salter MW, Orser BA, **Nakazawa T**, Yamamoto T, Jackson MF, MacDonald JF. Metaplasticity gated through differential regulation of GluN2A versus GluN2B receptors by Src family kinases. *EMBO J.* 31:805-816 (2012).
67. Yokoyama K, Tezuka T, Kotani M, **Nakazawa T**, Hoshina N, Shimoda Y, Kakuta S, Sudo K, Watanabe K, Iwakura Y, Yamamoto T. NYAP: a phosphoprotein family that links PI3K to WAVE1 signalling in neurons. *EMBO J.* 30:4739-4754 (2011).
68. Chen C, Ito K, Takahashi A, Wang G, Suzuki T, **Nakazawa T**, Yamamoto T, Yokoyama K. Distinct expression patterns of the subunits of the CCR4-NOT deadenylase complex during neural development. *Biochem. Biophys. Res. Commun.* 411:360-364 (2011).
69. Katano T, **Nakazawa T**, Nakatsuka T, Watanabe M, Yamamoto T, Ito S. Involvement of spinal phosphorylation cascade of Tyr1472-NR2B, Thr286-CaMKII, and Ser831-GluR1 in neuropathic pain. *Neuropharmacology* 60:609-616 (2011).
70. Delawary M, Tezuka T, Kiyama Y, Yokoyama K, Inoue T, Hattori S, Hashimoto R, Umemori H, Manabe T, Yamamoto T, **Nakazawa T**.^{CA} NMDAR2B tyrosine phosphorylation regulates anxiety-like behavior and CRF expression in the amygdala. (^{CA} corresponding author) *Mol. Brain* 3:37 (2010).
71. Matsumura S, Kunori S, Mabuchi T, Katano T, **Nakazawa T**, Abe T, Watanabe M, Yamamoto T, Okuda-Ashitaka E, Ito S. Impairment of CaMKII activation and attenuation of neuropathic pain in mice lacking NR2B phosphorylation at Tyr-1472. *Eur. J. Neurosci.* 32:798-810 (2010).
72. Chagnon MJ, Wu CL, **Nakazawa T**, Yamamoto T, Noda M, Blanchetot C, Tremblay ML. Receptor tyrosine

phosphatase sigma (RPTP σ) regulates, p250GAP, a novel substrate that attenuates Rac signaling.
Cell. Signal. 22:1626-1633 (2010).

73. Taniguchi S*, **Nakazawa T***^{CA}, Tanimura A*, Kiyama Y, Tezuka T, Watabe AM, Katayama N, Yokoyama K, Inoue T, Izumi-Nakaseko H, Kakuta S, Sudo K, Iwakura Y, Umemori H, Inoue T, Murphy NP, Hashimoto K, Kano M, Manabe T, Yamamoto T. Involvement of NMDAR2A tyrosine phosphorylation in depression-related behaviour. (* equal 1st author, ^{CA} corresponding author)
EMBO J. 28:3717-3729 (2009).
74. **Nakazawa T**, Kuriu T, Tezuka T, Umemori H, Okabe S, Yamamoto T. Regulation of dendritic spine morphology by an NMDA receptor-associated RhoGTPase-activating protein, p250GAP.
J. Neurochem. 105:1384-1393 (2008).
75. Isosaka T, Hattori K, Kida S, Kohno T, **Nakazawa T**, Yamamoto T, Yagi T, Yuasa S. Activation of Fyn tyrosine kinase in the mouse dorsal hippocampus is essential for contextual fear conditioning.
Eur. J. Neurosci. 28:973-981 (2008).
76. Goto J, Tezuka T, **Nakazawa T**, Sagara H, Yamamoto T. Loss of Fyn tyrosine kinase on the C57BL/6 genetic background causes hydrocephalus with defects in oligodendrocyte development.
Mol. Cell. Neurosci. 38:203-212 (2008).
77. Yamaguchi R, Wada E, Kamichi S, Yamada D, Maeno H, Delawary M, **Nakazawa T**, Yamamoto T, Wada K. Neurotensin type 2 receptor is involved in fear memory in mice.
J. Neurochem. 102:1669-1676 (2007).
78. Cheng HY, Papp JW, Varlamova O, Dziema H, Russell B, Curfman JP, **Nakazawa T**, Shimizu K, Okamura H, Impey S, Obrietan K. microRNA modulation of circadian-clock period and entrainment.
Neuron 54:813-829 (2007).
79. Delawary M, **Nakazawa T**, Tezuka T, Sawa M, Iino Y, Takenawa T, Yamamoto T. Molecular characterization of a novel RhoGAP, RRC-1 of the nematode *Caenorhabditis elegans*.
Biochem. Biophys. Res. Commun. 357:377-382 (2007).
80. **Nakazawa T***, Komai S*, Watabe AM*, Kiyama Y, Fukaya M, Arima-Yoshida F, Horai R, Sudo K, Ebine K, Delawary M, Goto J, Umemori H, Tezuka T, Iwakura Y, Watanabe M, Yamamoto T, Manabe T. NR2B tyrosine phosphorylation modulates fear learning as well as amygdaloid synaptic plasticity. (*equal 1st author)
EMBO J. 25:2867-2877 (2006).
81. Liu H*, **Nakazawa T***, Tezuka T, Yamamoto T. Physical and functional interaction of Fyn tyrosine kinase with a brain-enriched Rho GTPase-activating protein TCGAP. (*equal 1st author)
J. Biol. Chem. 281:23611-23619 (2006).
82. Kawa S, Ito C, Toyama Y, Maekawa M, Tezuka T, Nakamura T, **Nakazawa T**, Yokoyama K, Yoshida N, Toshimori K, Yamamoto T. Azoospermia in mice with targeted disruption of the *Brek/Lmtk2* (*brain-enriched kinase/lemur tyrosine kinase 2*) gene.
Proc. Natl. Acad. Sci. USA 103:19344-19349 (2006).
83. Yokoyama K, Tezuka T, Hoshina N, **Nakazawa T**, Yamamoto T. Phosphorylation at Tyr-694 of Nogo-A by Src-family kinases.
Biochem. Biophys. Res. Commun. 349:1401-1405 (2006).
84. Xu F, Plummer MR, Len GW, **Nakazawa T**, Yamamoto T, Black IB, Wu K. Brain-derived neurotrophic factor rapidly increases NMDA receptor channel activity through Fyn-mediated phosphorylation.
Brain Res. 1121:22-34 (2006).
85. Abe T, Matsumura S, Katano T, Mabuchi T, Takagi K, Xu L, Yamamoto A, Hattori K, Yagi T, Watanabe M, **Nakazawa T**, Yamamoto T, Mishina M, Nakai Y, Ito S. Fyn kinase-mediated phosphorylation of NMDA receptor NR2B subunit at Tyr1472 is essential for maintenance of neuropathic pain.
Eur. J. Neurosci. 22:1445-1454 (2005).
86. Kawa S, Fujimoto J, Tezuka T, **Nakazawa T**, Yamamoto T. Involvement of BREK, a serine/threonine kinase enriched in brain, in NGF signalling.
Genes Cells 9:219-232 (2004).
87. Goto J, Tezuka T, **Nakazawa T**, Tsukamoto N, Nakamura T, Ajima R, Yokoyama K, Ohta T, Ohki M, Yamamoto T. Altered gene expression in the adult brain of *fyn*-deficient mice.

Cell. Mol. Neurobiol. 24:149-159 (2004).

88. Nakazawa T, Watabe AM, Tezuka T, Yoshida Y, Yokoyama K, Umemori H, Inoue A, Okabe S, Manabe T, Yamamoto T. p250GAP, a novel brain-enriched GTPase-activating protein for Rho family GTPases, is involved in the *N*-methyl-D-aspartate receptor signaling. *Mol. Biol. Cell* 14:2921-2934 (2003).
89. Taniguchi S, Liu H, Nakazawa T, Yokoyama K, Tezuka T, Yamamoto T. p250GAP, a neural RhoGAP protein, is associated with and phosphorylated by Fyn. *Biochem. Biophys. Res. Commun.* 306:151-155 (2003).
90. Alvestad RM, Grosshans DR, Coultrap SJ, Nakazawa T, Yamamoto T, Browning MD. Tyrosine dephosphorylation and ethanol inhibition of *N*-methyl-D-aspartate receptor function. *J. Biol. Chem.* 278:11020-11025 (2003).
91. Gurd JW, Bissoon N, Beesley PW, Nakazawa T, Yamamoto T, Vannucci SJ. Differential effects of hypoxia-ischemia on subunit expression and tyrosine phosphorylation of the NMDA receptor in 7- and 21-day-old rats. *J. Neurochem.* 82:848-856 (2002).
92. Hashimoto R, Hough C, Nakazawa T, Yamamoto T, Chuang DM. Lithium protection against glutamate excitotoxicity in rat cerebral cortical neurons: involvement of NMDA receptor inhibition possibly by decreasing NR2B tyrosine phosphorylation. *J. Neurochem.* 80:589-597 (2002).
93. Nakazawa T, Komai S, Tezuka T, Hisatsune C, Umemori H, Semba K, Mishina M, Manabe T, Yamamoto T. Characterization of Fyn-mediated tyrosine phosphorylation sites on GluR epsilon 2 (NR2B) subunit of the *N*-methyl-D-aspartate receptor. *J. Biol. Chem.* 276:693-699 (2001).
94. Nakazawa T, Takahashi M, Horiuchi H, Ohta A, Takagi M. Cloning and characterization of *EPD2*, a gene required for efficient pseudohyphal formation of a dimorphic yeast, *Candida maltosa*. *Biosci., Biotechnol., Biochem.* 64:369-377 (2000).
95. Nakazawa T, Horiuchi H, Ohta A, Takagi M. Isolation and Characterization of *EPD1*, an essential gene for pseudohyphal growth of a dimorphic yeast, *Candida maltosa*. *J. Bacteriol.* 180:2079-2086 (1998).
96. Nakazawa T, Motoyama T, Horiuchi H, Ohta A, Takagi M. Evidence that part of a centromeric DNA region induces pseudohyphal growth in a dimorphic yeast, *Candida maltosa*. *J. Bacteriol.* 179:5030-5036 (1997).